Increased Mortality With Oral Platelet Glycoprotein IIb/IIIa Antagonists | Zendy

Derek P. Chew | Zendy; Deepak L. Bhatt | Zendy; Shelly Sapp | Zendy; Eric J. Topol | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Increased Mortality With Oral Platelet Glycoprotein IIb/IIIa Antagonists

Author(s) -

Derek P. Chew,

Deepak L. Bhatt,

Shelly Sapp,

Eric J. Topol

Publication year - 2001

Publication title -

circulation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 7.795

H-Index - 607

eISSN - 1524-4539

pISSN - 0009-7322

DOI - 10.1161/01.cir.103.2.201

Subject(s) - medicine , aspirin , myocardial infarction , placebo , revascularization , platelet aggregation inhibitor , randomized controlled trial , cardiology , coronary artery disease , pharmacology , gastroenterology , surgery , pathology , alternative medicine

Numerous clinical trials have established the benefits of intravenous glycoprotein IIb/IIIa inhibition in the management of coronary artery disease. In contrast, the recent large-scale, placebo-controlled, randomized trials of the oral glycoprotein IIb/IIIa antagonists have failed to provide commensurate reductions in late composite ischemic end points despite potent inhibition of platelet aggregation.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research